bioAffinity Technologies, Inc.

BIAF Nasdaq CIK: 0001712762

Company Information

Industry Services-Commercial Physical & Biological Research
SIC Code 8731
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 3300 NACOGDOCHES ROAD, SAN ANTONIO, TX, 78217
Mailing Address 3300 NACOGDOCHES ROAD, SAN ANTONIO, TX, 78217
Phone 210-698-5334
Fiscal Year End 1231
EIN 465211056

Financial Overview

FY2025

$7.28M
Stockholders' Equity

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events April 1, 2026 View on SEC
8-K Current report of material events March 26, 2026 View on SEC
8-K Current report of material events March 25, 2026 View on SEC
8-K Current report of material events March 17, 2026 View on SEC
DEF 14A Definitive proxy statement March 16, 2026 View on SEC
10-K Annual financial report March 16, 2026 View on SEC
8-K Current report of material events March 13, 2026 View on SEC
8-K Current report of material events March 10, 2026 View on SEC
8-K Current report of material events March 6, 2026 View on SEC
8-K Current report of material events March 3, 2026 View on SEC

Annual Reports

10-K March 16, 2026
  • Initial commercial launch of CyPath® Lung, generating first revenue.
  • Achieved a 150% revenue increase in 2025, signaling early commercial momentum.
View Analysis

Related Companies

Companies in the same industry (SIC: 8731)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.